Solvonis Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SVNS.L research report →
Companywww.graftpolymer.com
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds.
- CEO
- Anthony James Tennyson
- IPO
- 2022
- Employees
- 3
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $16.61M
- P/E
- -2.07
- P/S
- 0.00
- P/B
- 1.92
- EV/EBITDA
- -2.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.77%
- ROIC
- -48.94%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,740,000 · -261.01%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-3,477,000
- FCF YoY
- -188.62%
Performance & Tape
- 52W High
- $0.40
- 52W Low
- $0.13
- 50D MA
- $0.25
- 200D MA
- $0.28
- Beta
- 1.27
- Avg Volume
- 34.50M
Get TickerSpark's AI analysis on SVNS.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SVNS.L Coverage
We haven't published any research on SVNS.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SVNS.L Report →